Research by Area of Interest
Can Exosomes Help With Nerve Damage & Neuropathy? What the Research Says
Explore what published research is finding about extracellular vesicles, nerve regeneration, peripheral neuropathy and neuropathic pain.
What Does the Research Show?
“Nerve damage” and “neuropathy” describe several very different biological situations, and the research reflects that. Extracellular vesicles have been investigated in traumatic peripheral nerve injuries, nerve gaps and surgical nerve repair, diabetic peripheral neuropathy, neuropathic pain after nerve injury, axonal regeneration, myelin repair and Schwann-cell biology. The evidence is strongest in laboratory and animal research, but there are early signs of clinical translation. A 2025 review of EVs in peripheral nerve regeneration describes research involving immune modulation, axonal regrowth, remyelination and angiogenesis, along with newer approaches combining EVs with nerve conduits and engineered biomaterials. A 2025 systematic review and meta-analysis examining diabetic peripheral neuropathy identified 11 animal studies and reported favorable pooled findings involving nerve-conduction velocity, vascular measurements and several measurements of peripheral-nerve structure. And a 2024 pilot report described functional recovery in a single patient with a completely severed radial nerve after surgical nerve grafting combined with locally applied Wharton's-jelly-MSC-derived exosomes. The research is promising, but nerve damage is not one condition and extracellular-vesicle preparations are not one standardized product.
About the Research Discussed Here
The research discussed on this page did not evaluate HydroKarma products. Several highlighted studies involved extracellular vesicles produced from cultured mesenchymal stromal cells or Schwann-cell-related systems. The Li et al. study is particularly relevant because it investigated human-amniotic-fluid-derived exosomes, but those research materials were independently collected and prepared and were not HydroKarma. According to information supplied by KWEHEALTH, HydroKarma products are derived from refined human amniotic fluid rather than cultured-cell expansion. A shared source category does not establish that two independently manufactured extracellular-vesicle preparations have the same composition or biological effects. The findings discussed here therefore should not be interpreted as evidence that HydroKarma repairs damaged nerves, treats diabetic neuropathy or relieves neuropathic pain. Express Biologics presents this literature to help readers understand why extracellular vesicles are being investigated in nerve repair, neuropathy and neuropathic-pain research and what scientists have reported so far. For background on why preparations differ, see are all exosome products the same?.
Nerve damage can affect nearly every part of daily life.
Depending on which nerves are involved, people may experience weakness, numbness, burning, tingling, abnormal sensitivity, loss of coordination or persistent pain.
That has made nerve repair an important area of extracellular-vesicle and exosome research.
Scientists are investigating whether the biological signals carried by extracellular vesicles can influence processes involved in axon regeneration, myelin formation, inflammation, blood-vessel development and communication between neurons, Schwann cells and immune cells. Recent reviews describe encouraging findings across peripheral-nerve-regeneration models, although much of the research remains preclinical.
The field has also begun to move into people.
A 2024 pilot report described functional recovery in a patient with a completely severed radial nerve after surgical nerve grafting combined with locally applied Wharton's-jelly-MSC-derived exosomes.
So what exactly is the research finding?
What Does the Research Show?
The first thing to understand is that “nerve damage” and “neuropathy” describe several very different biological situations.
Research has investigated extracellular vesicles in:
- traumatic peripheral nerve injuries
- nerve gaps and surgical nerve repair
- diabetic peripheral neuropathy
- neuropathic pain after nerve injury
- axonal regeneration
- myelin repair
- Schwann-cell biology
The evidence is strongest in laboratory and animal research, but there are early signs of clinical translation.
A 2025 review of EVs in peripheral nerve regeneration describes research involving immune modulation, axonal regrowth, remyelination and angiogenesis, along with newer approaches combining EVs with nerve conduits and engineered biomaterials.
Meanwhile, a 2025 systematic review and meta-analysis specifically examining diabetic peripheral neuropathy identified 11 animal studies and reported favorable pooled findings involving nerve-conduction velocity, vascular measurements and several measurements of peripheral-nerve structure.
That gives researchers several different reasons to continue investigating extracellular vesicles in nerve biology.
Why Are Exosomes Being Studied for Nerve Repair?
Peripheral nerves have some natural ability to regenerate after injury.
But successful recovery requires a complicated sequence of events.
Damaged axons need to regrow.
Schwann cells help support regenerating axons and contribute to myelin formation.
Immune cells participate in clearing damaged tissue and coordinating the repair environment.
Blood supply needs to support healing tissue.
And the regenerating axon ultimately has to reconnect appropriately with its target.
Extracellular vesicles are interesting because these processes depend heavily on cell-to-cell communication.
EVs can carry proteins, lipids, messenger molecules and regulatory RNAs from one cell to another.
Schwann-cell-derived exosomes in particular have been studied for effects involving:
- axonal regeneration
- myelin formation
- neuroprotection
- inflammatory regulation
- vascular regeneration
- neural signaling
A 2024 review devoted specifically to Schwann-cell-derived exosomes describes these as recurring areas of experimental investigation in peripheral nerve repair.
What Are Researchers Finding in Peripheral Nerve Models?
The experimental evidence is considerably larger than the human evidence.
Researchers have tested extracellular vesicles in models of nerve crush, nerve transection and larger nerve defects.
One particularly interesting 2024 study used extracellular vesicles derived from skin-derived precursor Schwann cells inside tissue-engineered nerve grafts designed to bridge a 40-mm sciatic nerve defect in dogs.
Researchers reported improvements involving:
- hind-limb motor recovery
- electrophysiological function
- axonal growth
- myelination
- target-muscle preservation
The authors also investigated the molecular cargo inside the EVs and identified miR-30b-5p as an important contributor to the observed regenerative signaling.
That's notable because the research wasn't limited to asking whether the nerve “looked better.”
The investigators examined function, electrophysiology, axonal regeneration and molecular mechanisms.
Important limitation
This was still an animal experiment using an engineered nerve graft. It does not establish that applying an EV product to a human nerve injury would reproduce those outcomes. But it helps researchers understand how EVs may participate in the regeneration process.
What About Diabetic Peripheral Neuropathy?
Diabetic peripheral neuropathy is very different from a severed nerve.
Instead of one localized traumatic injury, diabetes can progressively damage peripheral nerves through metabolic, vascular, inflammatory and cellular mechanisms.
People may develop:
- numbness
- burning
- tingling
- altered pain sensitivity
- loss of sensation
- weakness
- reduced nerve conduction
Researchers have therefore investigated whether extracellular vesicles could influence nerve function, blood supply, inflammation and nerve structure in diabetic neuropathy.
A 2025 systematic review and meta-analysis specifically evaluated cell-derived exosome therapy in preclinical diabetic-peripheral-neuropathy models.
The review identified 11 studies.
What Did the Diabetic Neuropathy Meta-Analysis Find?
Across the included animal studies, pooled analyses reported favorable findings involving several different categories.
Nerve conduction
The meta-analysis reported improvements in both motor nerve-conduction velocity and sensory nerve-conduction velocity.
That's important because nerve conduction provides an electrophysiological measure of how effectively signals travel along peripheral nerves.
Peripheral nerve structure
Researchers also reported favorable changes involving:
- sciatic-nerve fiber diameter
- axon diameter
- myelin-sheath thickness
Those measurements provide structural information beyond pain behavior alone.
Blood flow and vascular measures
The pooled studies also reported improvements in:
- plantar blood-flow perfusion
- sciatic-nerve blood-flow perfusion
- vessel density
This is especially interesting because diabetic peripheral neuropathy isn't solely a neuronal problem; vascular dysfunction can also affect the peripheral-nerve environment.
Pain-related behavior
The analysis also examined neuropathic-pain behaviors.
It reported a significant pooled improvement in thermal hyperalgesia, while the pooled mechanical-allodynia result was not statistically significant.
That distinction matters.
Even within a positive research field, different outcomes don't necessarily respond identically.
What is the important limitation?
All 11 studies were preclinical animal studies. The reviewers also described the overall risk of bias as generally unclear and reported substantial heterogeneity across several pooled outcomes. So the meta-analysis provides strong justification for continued investigation—but not proof that exosomes treat diabetic neuropathy in people.
Amniotic Fluid Source Does Not Mean Identical Product
This deserves special emphasis.
HydroKarma is described by KWEHEALTH as being produced from refined human amniotic fluid.
The Li study also investigated extracellular vesicles isolated from human amniotic fluid.
That's scientifically interesting.
But it would be inappropriate to say: “This study proves HydroKarma produces these effects.”
Two amniotic-fluid-derived preparations can still differ in:
- donor characteristics
- gestational stage
- collection
- processing
- filtration
- isolation
- purification
- particle concentration
- characterization
- formulation
- storage
The study itself even found differences between second- and third-trimester amniotic-fluid-derived exosomes in its experimental model.
That is another reminder that biological source matters—but source alone doesn't make two preparations identical. For more on how sourcing differs across the field, see where do exosomes come from.
What About Schwann Cells?
Schwann cells are central to peripheral nerve repair.
After nerve injury, these cells undergo major changes that help clear damaged myelin, support axonal regrowth and ultimately contribute to remyelination.
Researchers have discovered that Schwann cells also communicate through extracellular vesicles.
A 2024 review of Schwann-cell-derived exosomes describes experimental findings involving:
- axonal regeneration
- myelin formation
- reduction of inflammation
- vascular regeneration
- neuroprotection
and identifies these pathways as important areas for continued peripheral-nerve research.
Researchers are also studying the specific microRNAs carried by these vesicles and how they influence neural repair.
That suggests that EV research isn't merely about delivering “particles.”
Scientists are increasingly asking: What information is being carried inside the particles?
Why Myelin Matters
Axons are often surrounded by myelin, an insulating structure that helps electrical impulses travel efficiently.
Damage to peripheral nerves can disrupt both the axon and its myelin.
That's why nerve research frequently measures more than whether an axon simply grows longer.
Researchers may examine:
- myelin thickness
- axon diameter
- nerve-fiber diameter
- electrical conduction
- motor function
- sensory function
The 2025 diabetic-neuropathy meta-analysis reported favorable pooled changes in several of these measures, including myelin-sheath thickness, axonal diameter and nerve-conduction velocity in animal models.
This gives researchers a more complete view of the repair process.
Nerve Damage, Neuropathy and Neuropathic Pain Are Not the Same Thing
This is probably the most important consumer distinction in the article.
A person with a severed radial nerve has a very different biological problem from someone with diabetic peripheral neuropathy.
And both are different from someone experiencing neuropathic pain after an injury.
Those conditions may share certain mechanisms, such as inflammation or altered neuronal signaling, but they aren't interchangeable diagnoses.
That's why we shouldn't take a result from one research model and automatically apply it to another. The same caution applies elsewhere in the literature — see, for example, back pain and disc degeneration and rotator cuff and tendon injuries.
The human radial-nerve pilot investigated traumatic nerve transection and surgical reconstruction.
The diabetic-neuropathy meta-analysis evaluated chronic metabolic peripheral-nerve damage in animals.
The human-amniotic-fluid study investigated neuropathic pain after experimentally induced nerve injury in mice.
Each contributes a different piece of information.
Why EV Source and Preparation Matter
The nerve literature again demonstrates that “exosomes” are not one standardized biological substance.
The studies discussed here include:
- Wharton's-jelly-MSC-derived EVs
- Schwann-cell-derived EVs
- bone-marrow-MSC-derived EVs
- adipose-MSC-derived EVs
- human-amniotic-fluid-derived exosomes
- engineered EVs
- EVs incorporated into nerve grafts and biomaterials
Their biology can differ substantially.
Preparations can also vary in:
- culture conditions
- cell passage
- isolation
- purification
- particle counting
- characterization
- molecular cargo
- dose
- formulation
- storage
- route of administration
Recent reviews of peripheral nerve regeneration emphasize standardization and scalable manufacturing as continuing challenges for clinical translation. How a preparation is measured and documented is itself part of that picture — see extracellular vesicle characterization and testing.
That means the most useful question when reading a study isn't simply: “Did they use exosomes?” It's: “What exactly did they use?”
Why Results May Vary
As with many biologically active interventions, people may not respond identically. Individual genetics, age, underlying biology, disease severity and other person-specific factors may influence biological responses. The extracellular-vesicle preparation itself—including its source, manufacturing, characterization and formulation—may also matter. Researchers are still working to understand which factors may help predict how individuals respond.
For nerve-related conditions, another important variable is the type and severity of nerve damage itself.
A partially injured nerve is not the same as a completely transected nerve.
A fresh traumatic injury is not the same as years of diabetic peripheral neuropathy.
Damage primarily affecting myelin may behave differently from severe axonal loss.
And chronic neuropathic pain may persist even after the original tissue injury has changed.
Those differences are one reason future clinical research will need to identify not simply whether an EV approach produces an average effect, but which types of nerve conditions and which patients are most likely to respond.
The Bottom Line
Extracellular-vesicle research involving peripheral nerves has developed into a broad and increasingly sophisticated field.
Laboratory and animal studies have reported encouraging findings involving:
- axonal regeneration
- myelin formation
- nerve conduction
- neuroinflammation
- vascular support
- peripheral-nerve structure
A 2025 meta-analysis of diabetic-peripheral-neuropathy animal studies reported favorable pooled findings across nerve conduction, vascular measures and several structural nerve measurements.
Peripheral-nerve research has also begun moving into people.
A 2024 pilot report described substantial motor, sensory and electrophysiological recovery following surgical reconstruction of a completely severed radial nerve combined with locally applied MSC-derived exosomes—although the single-patient design and concurrent nerve graft mean the EV contribution cannot be isolated.
And research using human-amniotic-fluid-derived exosomes has reported encouraging anti-inflammatory and neuropathic-pain findings in an experimental nerve-injury model, providing another biologically distinct direction for the field.
The research is promising.
But nerve damage is not one condition, and extracellular-vesicle preparations are not one standardized product. For the questions that distinguish one preparation from another, see what to look for when comparing exosome products.
Continued clinical research will be necessary to determine which EV sources, formulations and approaches are most relevant to different types of nerve injury and neuropathy.
Individual results can vary
Promising results in a study do not mean every person will experience the same result. Individual responses can vary, and researchers are still investigating why.
Research Highlights
Effects of exosomes from mesenchymal stem cells on functional recovery of a patient with total radial nerve injury: A pilot study
World Journal of Stem Cells · 2024 · One 24-year-old man with a complete left radial-nerve injury below the elbow caused by a knife wound, followed for 180 days
Exosome preparation produced from cultured Wharton's-jelly-derived mesenchymal stem cells: conditioned medium processed by sequential centrifugation followed by ultracentrifugation at 100,000 × g for 70 minutes, then evaluated by transmission electron microscopy and dynamic light scattering for morphology and size distribution
- What researchers studied
- Researchers repaired an approximately 7-centimeter radial-nerve gap using an 8.5-centimeter sural-nerve autograft and, during the same procedure, microsurgically applied 1 mL of an MSC-derived exosome preparation reported as containing 5 billion microvesicles, divided into four 0.25 mL volumes delivered through the subepineural pathway around the proximal and distal nerve stumps. The patient then underwent 180 days of neurological examination and electrodiagnostic testing.
- What researchers found
- The authors reported an advancing Tinel's sign together with sensory and motor recovery as early as the 10th week after nerve grafting, along with control electromyography showing signs of re-innervation despite persisting axonal damage. At six months, motor improvement was classified as M5 on the British Medical Research Council scale, described by the investigators as an excellent outcome, and sensory improvement was classified as S3+ on the Mackinnon-Dellon scale, a good outcome. Six-month electromyography showed significant electrophysiological improvement consistent with ongoing regeneration.
- Why this is interesting
- It is one of the rare published examples of exosome-associated peripheral-nerve research progressing into a human clinical case, and the recovery was documented with functional scales and electrodiagnostic testing rather than only a patient's impression.
- Important limitation
- This was one patient, and the exosomes were not used alone. The patient underwent major microsurgical nerve reconstruction with a sural-nerve autograft, so the study cannot determine how much of the recovery resulted from the surgical repair, the nerve graft, natural nerve regeneration, the EV preparation, or a combination of those factors. The authors themselves described the work as a pilot and called for prospective randomized clinical studies. The study did not evaluate HydroKarma.
DOI: 10.4252/wjsc.v16.i1.19 · PMID: 38292440
Human Amniotic Fluid-Derived Exosomes Alleviate Neuropathic Pain by Inducing an Anti-Inflammatory Transition in Microglia
FASEB Journal · 2025 · Kunming mice undergoing spared-nerve-injury surgery to induce neuropathic pain, plus laboratory experiments in lipopolysaccharide-stimulated BV2 microglial cells
Exosomes isolated directly from human amniotic fluid obtained from pregnant donors in the second or third trimester — not a preparation produced by expanding cultured cells, and not HydroKarma
- What researchers studied
- Researchers tested whether human amniotic-fluid-derived exosomes could alleviate neuropathic pain by modulating microglial homeostasis, using intrathecal administration in a spared-nerve-injury mouse model together with laboratory BV2 microglial experiments.
- What researchers found
- Fluorescein-labeled exosomes were detected in the ipsilateral dorsal horn of the spinal cord and in stimulated BV2 cells. Intrathecal administration alleviated mechanical allodynia in the ipsilateral hind paw of injured mice. The authors reported suppression of IL-1β, IL-6 and nitric oxide in microglia with increased IL-10, a reduced CD86+/CD206+ ratio in BV2 cells and upregulated Arg-1, consistent with a transition toward a more anti-inflammatory microglial state. Notably, the effects of second-trimester exosomes were reported as superior to those from third-trimester samples.
- Why this is interesting
- Most EV studies in this library used vesicles produced from cultured MSCs or other expanded cell populations; this one investigated exosomes isolated directly from human amniotic fluid, making the source scientifically different from many cultured-cell preparations in the literature.
- Important limitation
- Human source material does not make this a human clinical study. The therapeutic experiments were performed in mice and in laboratory microglial cells, so the work does not establish that amniotic-fluid-derived exosomes relieve neuropathic pain in people. The preparation studied was independently collected and prepared and was not HydroKarma; a shared source category does not make two preparations equivalent.
DOI: 10.1096/fj.202500334R · PMID: 40417920
Cell-derived exosome therapy for diabetic peripheral neuropathy: a preclinical animal studies systematic review and meta-analysis
Stem Cell Research & Therapy · 2025
Nine databases were searched from inception to February 2025, with study quality assessed using SYRCLE's risk-of-bias tool. Eleven preclinical animal studies of cell-derived exosomes in diabetic peripheral neuropathy were included, covering electrophysiological, behavioral and nerve-structure endpoints. The reviewers described the risk of bias in most studies as generally unclear and reported substantial heterogeneity across several pooled outcomes.
Key finding reported by the authors
Pooled analyses reported improvements in motor and sensory nerve-conduction velocity, in plantar and sciatic-nerve blood-flow perfusion and vessel density, and in sciatic-nerve fiber diameter, axon diameter and myelin-sheath thickness. Thermal hyperalgesia improved significantly, while the pooled mechanical-allodynia result was not statistically significant. All included studies were preclinical animal research, not human clinical evidence.
EV source / preparation: Included studies used exosomes from several sources, including Schwann-cell-derived, fibroblast-derived, bone-marrow-MSC-derived, other MSC-derived and plasma-derived preparations
View Original Research(opens in a new tab)Original Sources / References
- Civelek E, Kabatas S, Savrunlu EC, Diren F, Kaplan N, Ofluoğlu D, Karaöz E. — Effects of exosomes from mesenchymal stem cells on functional recovery of a patient with total radial nerve injury: A pilot study. World Journal of Stem Cells, 2024;16(1):19-32. DOI: 10.4252/wjsc.v16.i1.19 (PMID 38292440; PMCID PMC10824039). One 24-year-old right-hand-dominant male with left radial-nerve injury below the elbow from a knife assault; sural autograft repair followed by 1 mL of MSC-derived exosome preparation comprising 5 billion microvesicles, split into four 0.25 mL volumes delivered microsurgically via the subepineural pathway to the proximal and distal stumps; 180-day follow-up with neurological examination and electrodiagnostic testing; increasing Tinel's sign and sensory-motor recovery by the 10th week; M5 motor and S3+ sensory outcomes at six months; six-month EMG showing significant electrophysiological improvement indicating ongoing regeneration. Single-patient pilot study performed alongside surgical nerve grafting; the EV contribution cannot be isolated.
- Lu X, Xu R, Dong X, Bai D, Ji W, Chen X, Chen H, Hou C, Gao J. — Cell-derived exosome therapy for diabetic peripheral neuropathy: a preclinical animal studies systematic review and meta-analysis. Stem Cell Research & Therapy, 2025;16(1):297. DOI: 10.1186/s13287-025-04432-0 (PMID 40490808). Nine databases searched from inception to February 2025; 11 preclinical animal studies included, with risk of bias generally unclear; pooled improvements reported in motor nerve-conduction velocity (SMD 4.71, I² 91.8%) and sensory nerve-conduction velocity (SMD 1.07, I² 85.3%), thermal hyperalgesia (SMD −1.48, P = 0.003), plantar blood-flow perfusion, sciatic-nerve blood-flow perfusion and vessel density, and sciatic-nerve fiber diameter, axon diameter and myelin-sheath thickness; pooled mechanical allodynia was not statistically significant (P = 0.4697). Preclinical animal evidence only.
- Li Q, Dai H, Zhang S, Li P, Peng L, Chen Y, Guo Q, Yang Y. — Human Amniotic Fluid-Derived Exosomes Alleviate Neuropathic Pain by Inducing an Anti-Inflammatory Transition in Microglia. FASEB Journal, 2025;39(11):e70664. DOI: 10.1096/fj.202500334R (PMID 40417920). Exosomes isolated from amniotic fluid of pregnant women in their second or third trimesters; spared-nerve-injury surgery in Kunming mice plus LPS-stimulated BV2 microglial experiments; intrathecal administration alleviated mechanical allodynia; IL-1β, IL-6 and nitric oxide suppressed with IL-10 upregulated; reduced CD86+/CD206+ ratio and upregulated Arg-1; second-trimester exosome effects reported as superior to third-trimester. Animal and laboratory research, not a human clinical trial; the preparation was not HydroKarma.
- Chitosan/PLGA-based tissue engineered nerve grafts with SKP-SC-EVs enhance sciatic nerve regeneration in dogs through miR-30b-5p-mediated regulation of axon growth. Bioactive Materials, 2024;40:378-395. DOI: 10.1016/j.bioactmat.2024.06.011 (PMID 38978801). Extracellular vesicles from skin-derived precursor Schwann cells incorporated into chitosan/PLGA tissue-engineered nerve grafts bridging a 40-mm sciatic-nerve defect in dogs; reported improvements in hind-limb motor recovery, electrophysiological function, axonal growth and myelination, reduced target-muscle atrophy, and miR-30b-5p identified as a mediator of axon-growth regulation. Preclinical large-animal research, not human evidence.
- Wang JL, Huang QM, Hu DX, Zhang WJ. — Therapeutic effect of exosomes derived from Schwann cells in the repair of peripheral nerve injury. Life Sciences, 2024;357:123086. DOI: 10.1016/j.lfs.2024.123086 (PMID 39357794). Cited only as a narrative review describing experimental areas of investigation for Schwann-cell-derived exosomes in peripheral nerve repair, including axonal regeneration, myelin formation, inflammatory regulation, vascular regeneration and neuroprotection.
- Shi S, Yu X, Ou X, et al. — Extracellular Vesicles in Peripheral Nerve Regeneration: From Biology to Therapeutic Engineering. International Journal of Nanomedicine, 2025;20:11941-11957. DOI: 10.2147/IJN.S548357 (PMID 41041427). Cited only as a review providing broad mechanistic and translational context, including immune modulation, axonal regrowth, remyelination and angiogenesis, EV combination with nerve conduits and engineered biomaterials, and standardization and scalable manufacturing as continuing translational challenges.
Continue Learning
Can Exosomes Help With Back Pain & Disc Degeneration? What the Research Says
Explore what published research is finding about extracellular vesicles, low back pain, degenerative discs and spinal tissue repair.
Can Exosomes Help With Rotator Cuff & Tendon Injuries? What the Research Says
Explore what published research is finding about extracellular vesicles, rotator cuff repair, tendon healing and the tendon-to-bone interface.
Are All Exosome Products the Same?
Exosome and extracellular-vesicle products can differ in source, manufacturing approach, particle testing, characterization, documentation, format, storage and fulfillment.
Where Do Exosomes Come From? Comparing Common Sources
Extracellular vesicles can be obtained from biological fluids such as amniotic fluid or collected from cells grown in culture. Why the source changes the questions a buyer should ask.